Sophia Genetics reported a 16% year-over-year increase in Q2 2025 revenues, boosted by solid growth outside of a transient biopharma sector slowdown. The Swiss bioinformatics firm expanded its collaboration with AstraZeneca to apply multimodal artificial intelligence for advanced breast cancer research, combining genomics, imaging, and clinical data for real-world evidence generation. Despite a rise in R&D expenses and a widening net loss, the company expects to realize milestone revenues from this landmark partnership through 2026, positioning itself at the forefront of precision medicine data analytics.